Why is uniQure stock surging today?

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Zacks says uniQure is deeply oversold after the selloff and highlights technical and analyst estimate factors that could set the stage for a trend reversal, which could attract short‑term bargain hunters. Zacks: uniQure Loses 67.5% in 4 Weeks
• Neutral Sentiment: Mizuho assigned a Neutral rating on QURE (a non‑directional stance) — this may reduce bullish conviction but is not a hard negative. AmericanBankingNews: Mizuho Neutral
• Negative Sentiment: FDA told uniQure its Huntington’s trial did not provide sufficient evidence the therapy slowed disease progression and requested a new placebo‑controlled study — a major regulatory setback that increases development cost, delays potential approval and raises execution risk. Reuters: FDA official says UniQure fell short
• Negative Sentiment: A wave of securities‑class‑action notices and filings (multiple firms including Faruqi, Bernstein Liebhard, Rosen, Pomerantz, Levi & Korsinsky, Berger Montague and others) target purchases during Sept. 24–Oct. 31, 2025; they flag potential litigation exposure and could pressure investor sentiment and valuation. PR Newswire: Faruqi class action notice
• Negative Sentiment: Multiple analyst actions: Wells Fargo cut QURE from Overweight to Equal Weight and slashed its price target to $15 (from $60); Chardan trimmed its target to $16; Goldman Sachs issued a pessimistic forecast — these lower expectations amplify selling pressure and reduce upside conviction. Benzinga: Wells Fargo downgrade
• Negative Sentiment: News reports of large intraday volume and a multiday selloff (shares near 52‑week lows) indicate momentum is to the downside; that raises the chance of further near‑term volatility. Benzinga: What's Going On With uniQure Stock

Analyst Ratings Changes

QURE has been the subject of a number of recent research reports. Sanford C. Bernstein downgraded uniQure to a "market perform" rating in a research note on Tuesday. TD Cowen reaffirmed a "buy" rating on shares of uniQure in a research report on Tuesday. Wells Fargo & Company reissued an "equal weight" rating and issued a $15.00 target price (down from $60.00) on shares of uniQure in a research report on Tuesday. Leerink Partners restated an "outperform" rating and set a $35.00 price target on shares of uniQure in a research note on Monday. Finally, Royal Bank Of Canada lowered shares of uniQure from a "moderate buy" rating to a "hold" rating and set a $11.00 price objective for the company. in a research note on Monday. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $34.33.

uniQure Trading Up 13.5%

The firm has a market cap of $639.24 million, a P/E ratio of -3.03 and a beta of 0.73. The company's 50 day moving average is $22.54 and its two-hundred day moving average is $29.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, sell-side analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Activity

In related news, Director Jack Kaye sold 6,390 shares of the firm's stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company's stock, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business's stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 50,598 shares of company stock worth $1,248,588. 4.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Private Trust Co. NA acquired a new position in uniQure during the 3rd quarter worth about $28,000. Torren Management LLC bought a new position in shares of uniQure in the fourth quarter worth about $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of uniQure during the fourth quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $48,000. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Before you consider uniQure, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.

While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.